Method for diagnosis of alzheimer's disease with determination of LASP-1 immunoreactivity
Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.
1. A method for diagnosing Alzheimer's disease in a patient suspected of having Alzheimer's disease, the method comprising:
a) determining the concentration of LIM and SH3 Domain Protein-1 (LASP-1) in a blood or serum sample from said patient; and
b) comparing said concentrations to the corresponding concentration in a healthy control sample,
wherein an elevated concentration of LASP-1 protein in the sample from the patient suspected of having Alzheimer's disease is indicative of Alzheimer's disease.
2. The method of claim 1 , wherein the concentration of LASP-1 protein is determined by an immunodiagnostic assay of the sandwich type.
3. The method of claim 2 , wherein the LASP-1 determined is the LASP-1 protein from amino acid positions 121-187 of SEQ ID NO: 1.
4. The method of claim 2 , wherein the immunodiagnostic assay employs a pair of antibodies, wherein one of the antibodies of the pair is raised against a peptide comprising the amino acid sequence of SEQ ID NO:13 and the other antibody of the pair is raised against a peptide comprising the amino acid sequence of SEQ ID NO: 17.
5. The method of claim 3 , wherein the LASP-1 protein is in a posttranslational soluble form.
6. The method of claim 5 , wherein the protein is glycosylated.
7. The method of claim 5 , wherein the protein is phosphorylated.